A potential pharmacogenomic strategy for anticoagulant treatment in non-ST elevation acute coronary syndromes: The role of interleukin-1 receptor antagonist genotype

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 2, 2005, Pages 287-291

  Ray, K Kausik ^a,b   Francis, S ^a   Crossman, D C ^a  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b TIMI Study Group   (United States)

Author keywords

Anticoagulants; Genetics; Interleukins; Von Willebrand factor

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN; HEPARIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LOW MOLECULAR WEIGHT HEPARIN; VON WILLEBRAND FACTOR; ANTICOAGULANT AGENT; IL1RN PROTEIN, HUMAN; SIALOGLYCOPROTEIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DNA POLYMORPHISM; DOSE RESPONSE; FEMALE; GENE LOCUS; GENE TARGETING; GENOTYPE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PRIORITY JOURNAL; ACUTE DISEASE; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; ELECTROCARDIOGRAPHY; GENETIC POLYMORPHISM; GENETICS; METHODOLOGY; MIDDLE AGED; PHARMACOGENETICS; PHYSIOLOGY; TIME; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; ANTICOAGULANTS; CORONARY DISEASE; ELECTROCARDIOGRAPHY; FEMALE; GENOTYPE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SIALOGLYCOPROTEINS; TIME FACTORS; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 20844449426     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2005.01125.x     Document Type: Article

References (16)

1. Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D, Bayes De Luna A, Fox K, Lablanche JM, Radley D, Premmereur J, Braunwald E. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999; 100: 1593-601.
2. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447-52.
3. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998; 98: 294-9.
4. Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E, Perlemuter K, Philippe F, Drobinski G, Thomas D. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-14.
5. Paleolog EM, Crossman DC, McVey JH, Pearson JD. Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. Blood 1990; 75: 688-95.
6. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev 1997; 8: 253-65.
7. Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, Jeffery S, Kaski JC, Cumberland DC, Duff GW, Crossman DC. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999; 99: 861-6.
8. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2394-400.
9. Dewberry RM, Crossman DC, Francis SE. Interleukin-1 receptor antagonist (IL-IRN) genotype modulates the replicative capacity of human endothelial cells. Circ Res 2003; 92: 1285-7.
10. Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol 1996; 16: 1000-6.
11. Ishibashi T, Kijima M, Yokoyama K, Shindo J, Nagata K, Hirosaka A, Techigawara M, Abe Y, Sato E, Yamaguchi N, Watanabe N, Saito T, Maehara K, Ohmoto Y, Maruyama Y. Expression of cytokine and adhesion molecule mRNA in atherectomy specimens from patients with coronary artery disease. Jpn Circ J 1999; 63: 249-54.
12. Ray KK, Camp NJ, Bennett CE, Francis SE, Crossman DC. Genetic variation at the interleukin-1 locus is a determinant of changes in soluble endothelial factors in patients with acute coronary syndromes. Clin Sci (Lond), 2002; 103: 303-10.
13. Short PE, Williams CE, Picken AM, Hill FG, Factor VIII. related antigen: an improved enzyme immunoassay. Med Lab Sci 1982; 39: 351-5.
14. Antman EM, Cohen M, Bernink PJ, McCabe CH, Horacek T, Papuchis G, Mautner B, Corbalan R, Radley D, Braunwald E. The TIMI risk score for unstable angina/non-ST elevation MI. A method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-42.
15. Undas A, Brummel K, Musial J, Mann KG, Szczeklik A. PI(A2) polymorphism of beta(3) integrins is associated with enhanced thrombin generation and impaired antithrombotic action of aspirin at the site of microvascular injury. Circulation 2001; 104: 2666-72.
16. Carter MJ, Jones S, Camp NJ, Cox A, Mee J, Warren B, Duff GW, Lobo AJ, di Giovine FS. Functional correlates of the interleukin-1 receptor antagonist gene polymorphism in the colonic mucosa in ulcerative colitis. Genes Immun 2004; 5: 8-15.